Oxford Asset Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Oxford Asset Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-448	Closed	-$5K	–	1651
2018 Q4	$5K	Buy	+448	New	+$7.64K	﹤0.01%	1746
2016 Q2	–	Sell	-404	Closed	-$24K	–	791
2016 Q1	$24K	Sell	404 -3,730	-90%	-$236K	﹤0.01%	781
2015 Q4	$378K	Buy	+4,134	New	+$275K	0.01%	718

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Oxford Asset Management's ATNM Position: Q1 2019 in Review

Oxford Asset Management sold out of Actinium Pharmaceuticals (ATNM) in Q1 2019, closing a stake of 448 shares — an estimated $5K sold.

Oxford Asset Management first reported a position in ATNM in Q4 2015 and held it in 3 quarters. The position peaked at $378K in Q4 2015. 43 funds tracked by Wall St. Rank hold ATNM as of Q1 2019.

Oxford Asset Management reported no remaining Actinium Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 448 Actinium Pharmaceuticals shares in Q1 2019, an estimated $5K.
Oxford Asset Management first reported a position in Actinium Pharmaceuticals in Q4 2015 and held it in 3 quarters.
Oxford Asset Management's Actinium Pharmaceuticals position peaked at $378K in Q4 2015.
43 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.